Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis
Background: Non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are chronic inflammatory disorders with massive infiltration of eosinophils into the gastrointestinal tract. Food elimination diets are potentially effective treatments. But the existing dietary therapies have various...
Ausführliche Beschreibung
Autor*in: |
Saori Nagashima [verfasserIn] Mayu Yamamoto [verfasserIn] Yusuke Inuzuka [verfasserIn] Makoto Irahara [verfasserIn] Yumiko Miyaji [verfasserIn] Hiromi Tadaki [verfasserIn] Shuichi Ito [verfasserIn] Shizuka Masuda [verfasserIn] Yoshiyuki Ito [verfasserIn] Yuri Saito [verfasserIn] Saeko Kobayashi [verfasserIn] Hideaki Morita [verfasserIn] Takako Yoshioka [verfasserIn] Hirotaka Shimizu [verfasserIn] Katsuhiro Arai [verfasserIn] Yukihiro Ohya [verfasserIn] Hirohisa Saito [verfasserIn] Kenji Matsumoto [verfasserIn] Ichiro Nomura [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2023 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Allergology International - Elsevier, 2002, 72(2023), 2, Seite 306-315 |
---|---|
Übergeordnetes Werk: |
volume:72 ; year:2023 ; number:2 ; pages:306-315 |
Links: |
---|
DOI / URN: |
10.1016/j.alit.2022.11.001 |
---|
Katalog-ID: |
DOAJ088827224 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ088827224 | ||
003 | DE-627 | ||
005 | 20230501183740.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230410s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.alit.2022.11.001 |2 doi | |
035 | |a (DE-627)DOAJ088827224 | ||
035 | |a (DE-599)DOAJ900b9bc74c4646cabf2df89ae6f8dd96 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC581-607 | |
100 | 0 | |a Saori Nagashima |e verfasserin |4 aut | |
245 | 1 | 0 | |a Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background: Non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are chronic inflammatory disorders with massive infiltration of eosinophils into the gastrointestinal tract. Food elimination diets are potentially effective treatments. But the existing dietary therapies have various weak points. We developed a new regimen to compensate for the shortcomings of the elemental diet and 6-food elimination diet. The new regimen consists of an amino-acid-based formula, potatoes, vegetables, fruits and restricted seasonings. We named it the “Rainbow Elimination Diet (ED).” The aims of this study were to evaluate the tolerability and safety of this diet. Methods: A retrospective medical record examination was conducted at the National Center for Child Health and Development covering the period from January 2010 through December 2018. The medical records of patients (age 2–17 y) with histologically diagnosed non-EoE EGIDs were reviewed. The tolerability, nutritional intake, symptoms, and blood test findings were evaluated. Results: Nineteen patients were offered several kinds of food-elimination diets. Seven patients (eosinophilic gastritis: 5; gastroenteritis: 1; duodenitis: 1) were treated with Rainbow ED. Six patients were compliant with this diet. The median duration of the diet induction phase was 15 days (range 14–30). All 5 patients who had had symptoms just before the induction phase became symptom-free. The body weight decreased in 5 patients (median −0.6 kg), probably because the serum protein increased, resulting in reduced edema. All 5 patients with hypoproteinemia had elevated serum albumin (median 2.9–3.5 g/dL). The ingested nutritional elements were calculated, and most of them were sufficient, except for fat and selenium. Conclusions: The Rainbow ED was well-tolerated and safe for pediatric non-EoE EGIDs. | ||
650 | 4 | |a Eosinophilic duodenitis (EoD) | |
650 | 4 | |a Eosinophilic gastrointestinal disorders (EGID, EGIDs) | |
650 | 4 | |a Eosinophilic gastritis (EoG) | |
650 | 4 | |a Elimination diet (ED) | |
650 | 4 | |a Non-IgE-mediated gastrointestinal food allergy | |
653 | 0 | |a Immunologic diseases. Allergy | |
700 | 0 | |a Mayu Yamamoto |e verfasserin |4 aut | |
700 | 0 | |a Yusuke Inuzuka |e verfasserin |4 aut | |
700 | 0 | |a Makoto Irahara |e verfasserin |4 aut | |
700 | 0 | |a Yumiko Miyaji |e verfasserin |4 aut | |
700 | 0 | |a Hiromi Tadaki |e verfasserin |4 aut | |
700 | 0 | |a Shuichi Ito |e verfasserin |4 aut | |
700 | 0 | |a Shizuka Masuda |e verfasserin |4 aut | |
700 | 0 | |a Yoshiyuki Ito |e verfasserin |4 aut | |
700 | 0 | |a Yuri Saito |e verfasserin |4 aut | |
700 | 0 | |a Saeko Kobayashi |e verfasserin |4 aut | |
700 | 0 | |a Hideaki Morita |e verfasserin |4 aut | |
700 | 0 | |a Takako Yoshioka |e verfasserin |4 aut | |
700 | 0 | |a Hirotaka Shimizu |e verfasserin |4 aut | |
700 | 0 | |a Katsuhiro Arai |e verfasserin |4 aut | |
700 | 0 | |a Yukihiro Ohya |e verfasserin |4 aut | |
700 | 0 | |a Hirohisa Saito |e verfasserin |4 aut | |
700 | 0 | |a Kenji Matsumoto |e verfasserin |4 aut | |
700 | 0 | |a Ichiro Nomura |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Allergology International |d Elsevier, 2002 |g 72(2023), 2, Seite 306-315 |w (DE-627)320425320 |w (DE-600)2003098-8 |x 14401592 |7 nnns |
773 | 1 | 8 | |g volume:72 |g year:2023 |g number:2 |g pages:306-315 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.alit.2022.11.001 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/900b9bc74c4646cabf2df89ae6f8dd96 |z kostenfrei |
856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1323893022001265 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1323-8930 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 72 |j 2023 |e 2 |h 306-315 |
author_variant |
s n sn m y my y i yi m i mi y m ym h t ht s i si s m sm y i yi y s ys s k sk h m hm t y ty h s hs k a ka y o yo h s hs k m km i n in |
---|---|
matchkey_str |
article:14401592:2023----::oeaiiynsftoaeeiiainitopdarcoiohlc |
hierarchy_sort_str |
2023 |
callnumber-subject-code |
RC |
publishDate |
2023 |
allfields |
10.1016/j.alit.2022.11.001 doi (DE-627)DOAJ088827224 (DE-599)DOAJ900b9bc74c4646cabf2df89ae6f8dd96 DE-627 ger DE-627 rakwb eng RC581-607 Saori Nagashima verfasserin aut Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are chronic inflammatory disorders with massive infiltration of eosinophils into the gastrointestinal tract. Food elimination diets are potentially effective treatments. But the existing dietary therapies have various weak points. We developed a new regimen to compensate for the shortcomings of the elemental diet and 6-food elimination diet. The new regimen consists of an amino-acid-based formula, potatoes, vegetables, fruits and restricted seasonings. We named it the “Rainbow Elimination Diet (ED).” The aims of this study were to evaluate the tolerability and safety of this diet. Methods: A retrospective medical record examination was conducted at the National Center for Child Health and Development covering the period from January 2010 through December 2018. The medical records of patients (age 2–17 y) with histologically diagnosed non-EoE EGIDs were reviewed. The tolerability, nutritional intake, symptoms, and blood test findings were evaluated. Results: Nineteen patients were offered several kinds of food-elimination diets. Seven patients (eosinophilic gastritis: 5; gastroenteritis: 1; duodenitis: 1) were treated with Rainbow ED. Six patients were compliant with this diet. The median duration of the diet induction phase was 15 days (range 14–30). All 5 patients who had had symptoms just before the induction phase became symptom-free. The body weight decreased in 5 patients (median −0.6 kg), probably because the serum protein increased, resulting in reduced edema. All 5 patients with hypoproteinemia had elevated serum albumin (median 2.9–3.5 g/dL). The ingested nutritional elements were calculated, and most of them were sufficient, except for fat and selenium. Conclusions: The Rainbow ED was well-tolerated and safe for pediatric non-EoE EGIDs. Eosinophilic duodenitis (EoD) Eosinophilic gastrointestinal disorders (EGID, EGIDs) Eosinophilic gastritis (EoG) Elimination diet (ED) Non-IgE-mediated gastrointestinal food allergy Immunologic diseases. Allergy Mayu Yamamoto verfasserin aut Yusuke Inuzuka verfasserin aut Makoto Irahara verfasserin aut Yumiko Miyaji verfasserin aut Hiromi Tadaki verfasserin aut Shuichi Ito verfasserin aut Shizuka Masuda verfasserin aut Yoshiyuki Ito verfasserin aut Yuri Saito verfasserin aut Saeko Kobayashi verfasserin aut Hideaki Morita verfasserin aut Takako Yoshioka verfasserin aut Hirotaka Shimizu verfasserin aut Katsuhiro Arai verfasserin aut Yukihiro Ohya verfasserin aut Hirohisa Saito verfasserin aut Kenji Matsumoto verfasserin aut Ichiro Nomura verfasserin aut In Allergology International Elsevier, 2002 72(2023), 2, Seite 306-315 (DE-627)320425320 (DE-600)2003098-8 14401592 nnns volume:72 year:2023 number:2 pages:306-315 https://doi.org/10.1016/j.alit.2022.11.001 kostenfrei https://doaj.org/article/900b9bc74c4646cabf2df89ae6f8dd96 kostenfrei http://www.sciencedirect.com/science/article/pii/S1323893022001265 kostenfrei https://doaj.org/toc/1323-8930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 72 2023 2 306-315 |
spelling |
10.1016/j.alit.2022.11.001 doi (DE-627)DOAJ088827224 (DE-599)DOAJ900b9bc74c4646cabf2df89ae6f8dd96 DE-627 ger DE-627 rakwb eng RC581-607 Saori Nagashima verfasserin aut Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are chronic inflammatory disorders with massive infiltration of eosinophils into the gastrointestinal tract. Food elimination diets are potentially effective treatments. But the existing dietary therapies have various weak points. We developed a new regimen to compensate for the shortcomings of the elemental diet and 6-food elimination diet. The new regimen consists of an amino-acid-based formula, potatoes, vegetables, fruits and restricted seasonings. We named it the “Rainbow Elimination Diet (ED).” The aims of this study were to evaluate the tolerability and safety of this diet. Methods: A retrospective medical record examination was conducted at the National Center for Child Health and Development covering the period from January 2010 through December 2018. The medical records of patients (age 2–17 y) with histologically diagnosed non-EoE EGIDs were reviewed. The tolerability, nutritional intake, symptoms, and blood test findings were evaluated. Results: Nineteen patients were offered several kinds of food-elimination diets. Seven patients (eosinophilic gastritis: 5; gastroenteritis: 1; duodenitis: 1) were treated with Rainbow ED. Six patients were compliant with this diet. The median duration of the diet induction phase was 15 days (range 14–30). All 5 patients who had had symptoms just before the induction phase became symptom-free. The body weight decreased in 5 patients (median −0.6 kg), probably because the serum protein increased, resulting in reduced edema. All 5 patients with hypoproteinemia had elevated serum albumin (median 2.9–3.5 g/dL). The ingested nutritional elements were calculated, and most of them were sufficient, except for fat and selenium. Conclusions: The Rainbow ED was well-tolerated and safe for pediatric non-EoE EGIDs. Eosinophilic duodenitis (EoD) Eosinophilic gastrointestinal disorders (EGID, EGIDs) Eosinophilic gastritis (EoG) Elimination diet (ED) Non-IgE-mediated gastrointestinal food allergy Immunologic diseases. Allergy Mayu Yamamoto verfasserin aut Yusuke Inuzuka verfasserin aut Makoto Irahara verfasserin aut Yumiko Miyaji verfasserin aut Hiromi Tadaki verfasserin aut Shuichi Ito verfasserin aut Shizuka Masuda verfasserin aut Yoshiyuki Ito verfasserin aut Yuri Saito verfasserin aut Saeko Kobayashi verfasserin aut Hideaki Morita verfasserin aut Takako Yoshioka verfasserin aut Hirotaka Shimizu verfasserin aut Katsuhiro Arai verfasserin aut Yukihiro Ohya verfasserin aut Hirohisa Saito verfasserin aut Kenji Matsumoto verfasserin aut Ichiro Nomura verfasserin aut In Allergology International Elsevier, 2002 72(2023), 2, Seite 306-315 (DE-627)320425320 (DE-600)2003098-8 14401592 nnns volume:72 year:2023 number:2 pages:306-315 https://doi.org/10.1016/j.alit.2022.11.001 kostenfrei https://doaj.org/article/900b9bc74c4646cabf2df89ae6f8dd96 kostenfrei http://www.sciencedirect.com/science/article/pii/S1323893022001265 kostenfrei https://doaj.org/toc/1323-8930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 72 2023 2 306-315 |
allfields_unstemmed |
10.1016/j.alit.2022.11.001 doi (DE-627)DOAJ088827224 (DE-599)DOAJ900b9bc74c4646cabf2df89ae6f8dd96 DE-627 ger DE-627 rakwb eng RC581-607 Saori Nagashima verfasserin aut Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are chronic inflammatory disorders with massive infiltration of eosinophils into the gastrointestinal tract. Food elimination diets are potentially effective treatments. But the existing dietary therapies have various weak points. We developed a new regimen to compensate for the shortcomings of the elemental diet and 6-food elimination diet. The new regimen consists of an amino-acid-based formula, potatoes, vegetables, fruits and restricted seasonings. We named it the “Rainbow Elimination Diet (ED).” The aims of this study were to evaluate the tolerability and safety of this diet. Methods: A retrospective medical record examination was conducted at the National Center for Child Health and Development covering the period from January 2010 through December 2018. The medical records of patients (age 2–17 y) with histologically diagnosed non-EoE EGIDs were reviewed. The tolerability, nutritional intake, symptoms, and blood test findings were evaluated. Results: Nineteen patients were offered several kinds of food-elimination diets. Seven patients (eosinophilic gastritis: 5; gastroenteritis: 1; duodenitis: 1) were treated with Rainbow ED. Six patients were compliant with this diet. The median duration of the diet induction phase was 15 days (range 14–30). All 5 patients who had had symptoms just before the induction phase became symptom-free. The body weight decreased in 5 patients (median −0.6 kg), probably because the serum protein increased, resulting in reduced edema. All 5 patients with hypoproteinemia had elevated serum albumin (median 2.9–3.5 g/dL). The ingested nutritional elements were calculated, and most of them were sufficient, except for fat and selenium. Conclusions: The Rainbow ED was well-tolerated and safe for pediatric non-EoE EGIDs. Eosinophilic duodenitis (EoD) Eosinophilic gastrointestinal disorders (EGID, EGIDs) Eosinophilic gastritis (EoG) Elimination diet (ED) Non-IgE-mediated gastrointestinal food allergy Immunologic diseases. Allergy Mayu Yamamoto verfasserin aut Yusuke Inuzuka verfasserin aut Makoto Irahara verfasserin aut Yumiko Miyaji verfasserin aut Hiromi Tadaki verfasserin aut Shuichi Ito verfasserin aut Shizuka Masuda verfasserin aut Yoshiyuki Ito verfasserin aut Yuri Saito verfasserin aut Saeko Kobayashi verfasserin aut Hideaki Morita verfasserin aut Takako Yoshioka verfasserin aut Hirotaka Shimizu verfasserin aut Katsuhiro Arai verfasserin aut Yukihiro Ohya verfasserin aut Hirohisa Saito verfasserin aut Kenji Matsumoto verfasserin aut Ichiro Nomura verfasserin aut In Allergology International Elsevier, 2002 72(2023), 2, Seite 306-315 (DE-627)320425320 (DE-600)2003098-8 14401592 nnns volume:72 year:2023 number:2 pages:306-315 https://doi.org/10.1016/j.alit.2022.11.001 kostenfrei https://doaj.org/article/900b9bc74c4646cabf2df89ae6f8dd96 kostenfrei http://www.sciencedirect.com/science/article/pii/S1323893022001265 kostenfrei https://doaj.org/toc/1323-8930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 72 2023 2 306-315 |
allfieldsGer |
10.1016/j.alit.2022.11.001 doi (DE-627)DOAJ088827224 (DE-599)DOAJ900b9bc74c4646cabf2df89ae6f8dd96 DE-627 ger DE-627 rakwb eng RC581-607 Saori Nagashima verfasserin aut Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are chronic inflammatory disorders with massive infiltration of eosinophils into the gastrointestinal tract. Food elimination diets are potentially effective treatments. But the existing dietary therapies have various weak points. We developed a new regimen to compensate for the shortcomings of the elemental diet and 6-food elimination diet. The new regimen consists of an amino-acid-based formula, potatoes, vegetables, fruits and restricted seasonings. We named it the “Rainbow Elimination Diet (ED).” The aims of this study were to evaluate the tolerability and safety of this diet. Methods: A retrospective medical record examination was conducted at the National Center for Child Health and Development covering the period from January 2010 through December 2018. The medical records of patients (age 2–17 y) with histologically diagnosed non-EoE EGIDs were reviewed. The tolerability, nutritional intake, symptoms, and blood test findings were evaluated. Results: Nineteen patients were offered several kinds of food-elimination diets. Seven patients (eosinophilic gastritis: 5; gastroenteritis: 1; duodenitis: 1) were treated with Rainbow ED. Six patients were compliant with this diet. The median duration of the diet induction phase was 15 days (range 14–30). All 5 patients who had had symptoms just before the induction phase became symptom-free. The body weight decreased in 5 patients (median −0.6 kg), probably because the serum protein increased, resulting in reduced edema. All 5 patients with hypoproteinemia had elevated serum albumin (median 2.9–3.5 g/dL). The ingested nutritional elements were calculated, and most of them were sufficient, except for fat and selenium. Conclusions: The Rainbow ED was well-tolerated and safe for pediatric non-EoE EGIDs. Eosinophilic duodenitis (EoD) Eosinophilic gastrointestinal disorders (EGID, EGIDs) Eosinophilic gastritis (EoG) Elimination diet (ED) Non-IgE-mediated gastrointestinal food allergy Immunologic diseases. Allergy Mayu Yamamoto verfasserin aut Yusuke Inuzuka verfasserin aut Makoto Irahara verfasserin aut Yumiko Miyaji verfasserin aut Hiromi Tadaki verfasserin aut Shuichi Ito verfasserin aut Shizuka Masuda verfasserin aut Yoshiyuki Ito verfasserin aut Yuri Saito verfasserin aut Saeko Kobayashi verfasserin aut Hideaki Morita verfasserin aut Takako Yoshioka verfasserin aut Hirotaka Shimizu verfasserin aut Katsuhiro Arai verfasserin aut Yukihiro Ohya verfasserin aut Hirohisa Saito verfasserin aut Kenji Matsumoto verfasserin aut Ichiro Nomura verfasserin aut In Allergology International Elsevier, 2002 72(2023), 2, Seite 306-315 (DE-627)320425320 (DE-600)2003098-8 14401592 nnns volume:72 year:2023 number:2 pages:306-315 https://doi.org/10.1016/j.alit.2022.11.001 kostenfrei https://doaj.org/article/900b9bc74c4646cabf2df89ae6f8dd96 kostenfrei http://www.sciencedirect.com/science/article/pii/S1323893022001265 kostenfrei https://doaj.org/toc/1323-8930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 72 2023 2 306-315 |
allfieldsSound |
10.1016/j.alit.2022.11.001 doi (DE-627)DOAJ088827224 (DE-599)DOAJ900b9bc74c4646cabf2df89ae6f8dd96 DE-627 ger DE-627 rakwb eng RC581-607 Saori Nagashima verfasserin aut Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are chronic inflammatory disorders with massive infiltration of eosinophils into the gastrointestinal tract. Food elimination diets are potentially effective treatments. But the existing dietary therapies have various weak points. We developed a new regimen to compensate for the shortcomings of the elemental diet and 6-food elimination diet. The new regimen consists of an amino-acid-based formula, potatoes, vegetables, fruits and restricted seasonings. We named it the “Rainbow Elimination Diet (ED).” The aims of this study were to evaluate the tolerability and safety of this diet. Methods: A retrospective medical record examination was conducted at the National Center for Child Health and Development covering the period from January 2010 through December 2018. The medical records of patients (age 2–17 y) with histologically diagnosed non-EoE EGIDs were reviewed. The tolerability, nutritional intake, symptoms, and blood test findings were evaluated. Results: Nineteen patients were offered several kinds of food-elimination diets. Seven patients (eosinophilic gastritis: 5; gastroenteritis: 1; duodenitis: 1) were treated with Rainbow ED. Six patients were compliant with this diet. The median duration of the diet induction phase was 15 days (range 14–30). All 5 patients who had had symptoms just before the induction phase became symptom-free. The body weight decreased in 5 patients (median −0.6 kg), probably because the serum protein increased, resulting in reduced edema. All 5 patients with hypoproteinemia had elevated serum albumin (median 2.9–3.5 g/dL). The ingested nutritional elements were calculated, and most of them were sufficient, except for fat and selenium. Conclusions: The Rainbow ED was well-tolerated and safe for pediatric non-EoE EGIDs. Eosinophilic duodenitis (EoD) Eosinophilic gastrointestinal disorders (EGID, EGIDs) Eosinophilic gastritis (EoG) Elimination diet (ED) Non-IgE-mediated gastrointestinal food allergy Immunologic diseases. Allergy Mayu Yamamoto verfasserin aut Yusuke Inuzuka verfasserin aut Makoto Irahara verfasserin aut Yumiko Miyaji verfasserin aut Hiromi Tadaki verfasserin aut Shuichi Ito verfasserin aut Shizuka Masuda verfasserin aut Yoshiyuki Ito verfasserin aut Yuri Saito verfasserin aut Saeko Kobayashi verfasserin aut Hideaki Morita verfasserin aut Takako Yoshioka verfasserin aut Hirotaka Shimizu verfasserin aut Katsuhiro Arai verfasserin aut Yukihiro Ohya verfasserin aut Hirohisa Saito verfasserin aut Kenji Matsumoto verfasserin aut Ichiro Nomura verfasserin aut In Allergology International Elsevier, 2002 72(2023), 2, Seite 306-315 (DE-627)320425320 (DE-600)2003098-8 14401592 nnns volume:72 year:2023 number:2 pages:306-315 https://doi.org/10.1016/j.alit.2022.11.001 kostenfrei https://doaj.org/article/900b9bc74c4646cabf2df89ae6f8dd96 kostenfrei http://www.sciencedirect.com/science/article/pii/S1323893022001265 kostenfrei https://doaj.org/toc/1323-8930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 72 2023 2 306-315 |
language |
English |
source |
In Allergology International 72(2023), 2, Seite 306-315 volume:72 year:2023 number:2 pages:306-315 |
sourceStr |
In Allergology International 72(2023), 2, Seite 306-315 volume:72 year:2023 number:2 pages:306-315 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Eosinophilic duodenitis (EoD) Eosinophilic gastrointestinal disorders (EGID, EGIDs) Eosinophilic gastritis (EoG) Elimination diet (ED) Non-IgE-mediated gastrointestinal food allergy Immunologic diseases. Allergy |
isfreeaccess_bool |
true |
container_title |
Allergology International |
authorswithroles_txt_mv |
Saori Nagashima @@aut@@ Mayu Yamamoto @@aut@@ Yusuke Inuzuka @@aut@@ Makoto Irahara @@aut@@ Yumiko Miyaji @@aut@@ Hiromi Tadaki @@aut@@ Shuichi Ito @@aut@@ Shizuka Masuda @@aut@@ Yoshiyuki Ito @@aut@@ Yuri Saito @@aut@@ Saeko Kobayashi @@aut@@ Hideaki Morita @@aut@@ Takako Yoshioka @@aut@@ Hirotaka Shimizu @@aut@@ Katsuhiro Arai @@aut@@ Yukihiro Ohya @@aut@@ Hirohisa Saito @@aut@@ Kenji Matsumoto @@aut@@ Ichiro Nomura @@aut@@ |
publishDateDaySort_date |
2023-01-01T00:00:00Z |
hierarchy_top_id |
320425320 |
id |
DOAJ088827224 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ088827224</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501183740.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230410s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.alit.2022.11.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ088827224</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ900b9bc74c4646cabf2df89ae6f8dd96</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Saori Nagashima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are chronic inflammatory disorders with massive infiltration of eosinophils into the gastrointestinal tract. Food elimination diets are potentially effective treatments. But the existing dietary therapies have various weak points. We developed a new regimen to compensate for the shortcomings of the elemental diet and 6-food elimination diet. The new regimen consists of an amino-acid-based formula, potatoes, vegetables, fruits and restricted seasonings. We named it the “Rainbow Elimination Diet (ED).” The aims of this study were to evaluate the tolerability and safety of this diet. Methods: A retrospective medical record examination was conducted at the National Center for Child Health and Development covering the period from January 2010 through December 2018. The medical records of patients (age 2–17 y) with histologically diagnosed non-EoE EGIDs were reviewed. The tolerability, nutritional intake, symptoms, and blood test findings were evaluated. Results: Nineteen patients were offered several kinds of food-elimination diets. Seven patients (eosinophilic gastritis: 5; gastroenteritis: 1; duodenitis: 1) were treated with Rainbow ED. Six patients were compliant with this diet. The median duration of the diet induction phase was 15 days (range 14–30). All 5 patients who had had symptoms just before the induction phase became symptom-free. The body weight decreased in 5 patients (median −0.6 kg), probably because the serum protein increased, resulting in reduced edema. All 5 patients with hypoproteinemia had elevated serum albumin (median 2.9–3.5 g/dL). The ingested nutritional elements were calculated, and most of them were sufficient, except for fat and selenium. Conclusions: The Rainbow ED was well-tolerated and safe for pediatric non-EoE EGIDs.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Eosinophilic duodenitis (EoD)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Eosinophilic gastrointestinal disorders (EGID, EGIDs)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Eosinophilic gastritis (EoG)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Elimination diet (ED)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Non-IgE-mediated gastrointestinal food allergy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mayu Yamamoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yusuke Inuzuka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Makoto Irahara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yumiko Miyaji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiromi Tadaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shuichi Ito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shizuka Masuda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshiyuki Ito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuri Saito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Saeko Kobayashi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hideaki Morita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takako Yoshioka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hirotaka Shimizu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katsuhiro Arai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yukihiro Ohya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hirohisa Saito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kenji Matsumoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ichiro Nomura</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Allergology International</subfield><subfield code="d">Elsevier, 2002</subfield><subfield code="g">72(2023), 2, Seite 306-315</subfield><subfield code="w">(DE-627)320425320</subfield><subfield code="w">(DE-600)2003098-8</subfield><subfield code="x">14401592</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:72</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:306-315</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.alit.2022.11.001</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/900b9bc74c4646cabf2df89ae6f8dd96</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1323893022001265</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1323-8930</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">72</subfield><subfield code="j">2023</subfield><subfield code="e">2</subfield><subfield code="h">306-315</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Saori Nagashima |
spellingShingle |
Saori Nagashima misc RC581-607 misc Eosinophilic duodenitis (EoD) misc Eosinophilic gastrointestinal disorders (EGID, EGIDs) misc Eosinophilic gastritis (EoG) misc Elimination diet (ED) misc Non-IgE-mediated gastrointestinal food allergy misc Immunologic diseases. Allergy Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis |
authorStr |
Saori Nagashima |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)320425320 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC581-607 |
illustrated |
Not Illustrated |
issn |
14401592 |
topic_title |
RC581-607 Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis Eosinophilic duodenitis (EoD) Eosinophilic gastrointestinal disorders (EGID, EGIDs) Eosinophilic gastritis (EoG) Elimination diet (ED) Non-IgE-mediated gastrointestinal food allergy |
topic |
misc RC581-607 misc Eosinophilic duodenitis (EoD) misc Eosinophilic gastrointestinal disorders (EGID, EGIDs) misc Eosinophilic gastritis (EoG) misc Elimination diet (ED) misc Non-IgE-mediated gastrointestinal food allergy misc Immunologic diseases. Allergy |
topic_unstemmed |
misc RC581-607 misc Eosinophilic duodenitis (EoD) misc Eosinophilic gastrointestinal disorders (EGID, EGIDs) misc Eosinophilic gastritis (EoG) misc Elimination diet (ED) misc Non-IgE-mediated gastrointestinal food allergy misc Immunologic diseases. Allergy |
topic_browse |
misc RC581-607 misc Eosinophilic duodenitis (EoD) misc Eosinophilic gastrointestinal disorders (EGID, EGIDs) misc Eosinophilic gastritis (EoG) misc Elimination diet (ED) misc Non-IgE-mediated gastrointestinal food allergy misc Immunologic diseases. Allergy |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Allergology International |
hierarchy_parent_id |
320425320 |
hierarchy_top_title |
Allergology International |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)320425320 (DE-600)2003098-8 |
title |
Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis |
ctrlnum |
(DE-627)DOAJ088827224 (DE-599)DOAJ900b9bc74c4646cabf2df89ae6f8dd96 |
title_full |
Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis |
author_sort |
Saori Nagashima |
journal |
Allergology International |
journalStr |
Allergology International |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2023 |
contenttype_str_mv |
txt |
container_start_page |
306 |
author_browse |
Saori Nagashima Mayu Yamamoto Yusuke Inuzuka Makoto Irahara Yumiko Miyaji Hiromi Tadaki Shuichi Ito Shizuka Masuda Yoshiyuki Ito Yuri Saito Saeko Kobayashi Hideaki Morita Takako Yoshioka Hirotaka Shimizu Katsuhiro Arai Yukihiro Ohya Hirohisa Saito Kenji Matsumoto Ichiro Nomura |
container_volume |
72 |
class |
RC581-607 |
format_se |
Elektronische Aufsätze |
author-letter |
Saori Nagashima |
doi_str_mv |
10.1016/j.alit.2022.11.001 |
author2-role |
verfasserin |
title_sort |
tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis |
callnumber |
RC581-607 |
title_auth |
Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis |
abstract |
Background: Non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are chronic inflammatory disorders with massive infiltration of eosinophils into the gastrointestinal tract. Food elimination diets are potentially effective treatments. But the existing dietary therapies have various weak points. We developed a new regimen to compensate for the shortcomings of the elemental diet and 6-food elimination diet. The new regimen consists of an amino-acid-based formula, potatoes, vegetables, fruits and restricted seasonings. We named it the “Rainbow Elimination Diet (ED).” The aims of this study were to evaluate the tolerability and safety of this diet. Methods: A retrospective medical record examination was conducted at the National Center for Child Health and Development covering the period from January 2010 through December 2018. The medical records of patients (age 2–17 y) with histologically diagnosed non-EoE EGIDs were reviewed. The tolerability, nutritional intake, symptoms, and blood test findings were evaluated. Results: Nineteen patients were offered several kinds of food-elimination diets. Seven patients (eosinophilic gastritis: 5; gastroenteritis: 1; duodenitis: 1) were treated with Rainbow ED. Six patients were compliant with this diet. The median duration of the diet induction phase was 15 days (range 14–30). All 5 patients who had had symptoms just before the induction phase became symptom-free. The body weight decreased in 5 patients (median −0.6 kg), probably because the serum protein increased, resulting in reduced edema. All 5 patients with hypoproteinemia had elevated serum albumin (median 2.9–3.5 g/dL). The ingested nutritional elements were calculated, and most of them were sufficient, except for fat and selenium. Conclusions: The Rainbow ED was well-tolerated and safe for pediatric non-EoE EGIDs. |
abstractGer |
Background: Non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are chronic inflammatory disorders with massive infiltration of eosinophils into the gastrointestinal tract. Food elimination diets are potentially effective treatments. But the existing dietary therapies have various weak points. We developed a new regimen to compensate for the shortcomings of the elemental diet and 6-food elimination diet. The new regimen consists of an amino-acid-based formula, potatoes, vegetables, fruits and restricted seasonings. We named it the “Rainbow Elimination Diet (ED).” The aims of this study were to evaluate the tolerability and safety of this diet. Methods: A retrospective medical record examination was conducted at the National Center for Child Health and Development covering the period from January 2010 through December 2018. The medical records of patients (age 2–17 y) with histologically diagnosed non-EoE EGIDs were reviewed. The tolerability, nutritional intake, symptoms, and blood test findings were evaluated. Results: Nineteen patients were offered several kinds of food-elimination diets. Seven patients (eosinophilic gastritis: 5; gastroenteritis: 1; duodenitis: 1) were treated with Rainbow ED. Six patients were compliant with this diet. The median duration of the diet induction phase was 15 days (range 14–30). All 5 patients who had had symptoms just before the induction phase became symptom-free. The body weight decreased in 5 patients (median −0.6 kg), probably because the serum protein increased, resulting in reduced edema. All 5 patients with hypoproteinemia had elevated serum albumin (median 2.9–3.5 g/dL). The ingested nutritional elements were calculated, and most of them were sufficient, except for fat and selenium. Conclusions: The Rainbow ED was well-tolerated and safe for pediatric non-EoE EGIDs. |
abstract_unstemmed |
Background: Non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are chronic inflammatory disorders with massive infiltration of eosinophils into the gastrointestinal tract. Food elimination diets are potentially effective treatments. But the existing dietary therapies have various weak points. We developed a new regimen to compensate for the shortcomings of the elemental diet and 6-food elimination diet. The new regimen consists of an amino-acid-based formula, potatoes, vegetables, fruits and restricted seasonings. We named it the “Rainbow Elimination Diet (ED).” The aims of this study were to evaluate the tolerability and safety of this diet. Methods: A retrospective medical record examination was conducted at the National Center for Child Health and Development covering the period from January 2010 through December 2018. The medical records of patients (age 2–17 y) with histologically diagnosed non-EoE EGIDs were reviewed. The tolerability, nutritional intake, symptoms, and blood test findings were evaluated. Results: Nineteen patients were offered several kinds of food-elimination diets. Seven patients (eosinophilic gastritis: 5; gastroenteritis: 1; duodenitis: 1) were treated with Rainbow ED. Six patients were compliant with this diet. The median duration of the diet induction phase was 15 days (range 14–30). All 5 patients who had had symptoms just before the induction phase became symptom-free. The body weight decreased in 5 patients (median −0.6 kg), probably because the serum protein increased, resulting in reduced edema. All 5 patients with hypoproteinemia had elevated serum albumin (median 2.9–3.5 g/dL). The ingested nutritional elements were calculated, and most of them were sufficient, except for fat and selenium. Conclusions: The Rainbow ED was well-tolerated and safe for pediatric non-EoE EGIDs. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
2 |
title_short |
Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis |
url |
https://doi.org/10.1016/j.alit.2022.11.001 https://doaj.org/article/900b9bc74c4646cabf2df89ae6f8dd96 http://www.sciencedirect.com/science/article/pii/S1323893022001265 https://doaj.org/toc/1323-8930 |
remote_bool |
true |
author2 |
Mayu Yamamoto Yusuke Inuzuka Makoto Irahara Yumiko Miyaji Hiromi Tadaki Shuichi Ito Shizuka Masuda Yoshiyuki Ito Yuri Saito Saeko Kobayashi Hideaki Morita Takako Yoshioka Hirotaka Shimizu Katsuhiro Arai Yukihiro Ohya Hirohisa Saito Kenji Matsumoto Ichiro Nomura |
author2Str |
Mayu Yamamoto Yusuke Inuzuka Makoto Irahara Yumiko Miyaji Hiromi Tadaki Shuichi Ito Shizuka Masuda Yoshiyuki Ito Yuri Saito Saeko Kobayashi Hideaki Morita Takako Yoshioka Hirotaka Shimizu Katsuhiro Arai Yukihiro Ohya Hirohisa Saito Kenji Matsumoto Ichiro Nomura |
ppnlink |
320425320 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1016/j.alit.2022.11.001 |
callnumber-a |
RC581-607 |
up_date |
2024-07-03T19:44:00.730Z |
_version_ |
1803588301735591936 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ088827224</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501183740.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230410s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.alit.2022.11.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ088827224</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ900b9bc74c4646cabf2df89ae6f8dd96</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Saori Nagashima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are chronic inflammatory disorders with massive infiltration of eosinophils into the gastrointestinal tract. Food elimination diets are potentially effective treatments. But the existing dietary therapies have various weak points. We developed a new regimen to compensate for the shortcomings of the elemental diet and 6-food elimination diet. The new regimen consists of an amino-acid-based formula, potatoes, vegetables, fruits and restricted seasonings. We named it the “Rainbow Elimination Diet (ED).” The aims of this study were to evaluate the tolerability and safety of this diet. Methods: A retrospective medical record examination was conducted at the National Center for Child Health and Development covering the period from January 2010 through December 2018. The medical records of patients (age 2–17 y) with histologically diagnosed non-EoE EGIDs were reviewed. The tolerability, nutritional intake, symptoms, and blood test findings were evaluated. Results: Nineteen patients were offered several kinds of food-elimination diets. Seven patients (eosinophilic gastritis: 5; gastroenteritis: 1; duodenitis: 1) were treated with Rainbow ED. Six patients were compliant with this diet. The median duration of the diet induction phase was 15 days (range 14–30). All 5 patients who had had symptoms just before the induction phase became symptom-free. The body weight decreased in 5 patients (median −0.6 kg), probably because the serum protein increased, resulting in reduced edema. All 5 patients with hypoproteinemia had elevated serum albumin (median 2.9–3.5 g/dL). The ingested nutritional elements were calculated, and most of them were sufficient, except for fat and selenium. Conclusions: The Rainbow ED was well-tolerated and safe for pediatric non-EoE EGIDs.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Eosinophilic duodenitis (EoD)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Eosinophilic gastrointestinal disorders (EGID, EGIDs)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Eosinophilic gastritis (EoG)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Elimination diet (ED)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Non-IgE-mediated gastrointestinal food allergy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mayu Yamamoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yusuke Inuzuka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Makoto Irahara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yumiko Miyaji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiromi Tadaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shuichi Ito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shizuka Masuda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshiyuki Ito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuri Saito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Saeko Kobayashi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hideaki Morita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takako Yoshioka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hirotaka Shimizu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katsuhiro Arai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yukihiro Ohya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hirohisa Saito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kenji Matsumoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ichiro Nomura</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Allergology International</subfield><subfield code="d">Elsevier, 2002</subfield><subfield code="g">72(2023), 2, Seite 306-315</subfield><subfield code="w">(DE-627)320425320</subfield><subfield code="w">(DE-600)2003098-8</subfield><subfield code="x">14401592</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:72</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:306-315</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.alit.2022.11.001</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/900b9bc74c4646cabf2df89ae6f8dd96</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1323893022001265</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1323-8930</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">72</subfield><subfield code="j">2023</subfield><subfield code="e">2</subfield><subfield code="h">306-315</subfield></datafield></record></collection>
|
score |
7.39931 |